.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Targeting Angiogenesis with Chemotherapy for Advanced Breast Cancer

EP. 1: Chemotherapy for Metastatic Breast Cancer in 2017

April 19th 2017

EP. 2: Chemotherapy Use for Breast Cancer Subtypes

April 19th 2017

EP. 3: Optimizing Chemotherapy for Metastatic Breast Cancer

April 19th 2017

EP. 4: Evolution of Chemotherapy for Metastatic Breast Cancer

April 19th 2017

EP. 5: Role of MOA When Choosing Breast Cancer Chemotherapy

April 19th 2017

EP. 6: Dual MOA for Eribulin in Breast Cancer

April 19th 2017

EP. 7: Preclinical Observations on Eribulin for Breast Cancer

April 19th 2017

EP. 8: Patient Selection for Eribulin in Breast Cancer

April 19th 2017

EP. 9: Unmet Needs for Metastatic Breast Cancer

April 19th 2017

EP. 10: Future Directions for Metastatic Breast Cancer

April 19th 2017